


Razoxane

Cat. No.:	HY-119425
CAS No.:	21416-67-1
Molecular Formula:	C ₁₁ H ₁₆ N ₄ O ₄
Molecular Weight:	268.27
Target:	Topoisomerase
Pathway:	Cell Cycle/DNA Damage
Storage:	Please store the product under the recommended conditions in the Certificate of Analysis.



BIOLOGICAL ACTIVITY

Description	Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC) ^[1] .									
IC₅₀ & Target	Topoisomerase II									
In Vitro	Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model. MCE has not independently confirmed the accuracy of these methods. They are for reference only.									
In Vivo	<p>Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)^[2].</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 30%;">Animal Model:</td> <td>Sprague-Dawley rats^[2]</td> </tr> <tr> <td>Dosage:</td> <td>30 mg/kg or 10 mg/kg per day</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation</td> </tr> <tr> <td>Result:</td> <td>Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.</td> </tr> </table>		Animal Model:	Sprague-Dawley rats ^[2]	Dosage:	30 mg/kg or 10 mg/kg per day	Administration:	Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation	Result:	Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
Animal Model:	Sprague-Dawley rats ^[2]									
Dosage:	30 mg/kg or 10 mg/kg per day									
Administration:	Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation									
Result:	Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.									

REFERENCES

[1]. J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6(12):4697-704.

[2]. F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis. Jan-Mar 1987; 5(1):9-16.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA